Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)

被引：208

作者：

Ghezzi, A ^{[1
]}

Aceto, M ^{[1
]}

Cassino, C ^{[1
]}

Gabano, E ^{[1
]}

Osella, D ^{[1
]}

机构：

[1] Univ Piemonte Orientale, Dipartimento Sci & Tecnol Avanzate, I-15100 Alessandria, Italy

来源：

JOURNAL OF INORGANIC BIOCHEMISTRY | 2004年 / 98卷 / 01期

关键词：

antitumor chemotherapy; cisplatin-like complexes; platinum uptake; ICP-MS;

D O I：

10.1016/j.jinorgbio.2003.08.014

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A systematic study on intracellular Pt uptake and Pt accumulation ratio in breast cancer MCF-7 cell line has been performed on a number of Pt(II)-complexes, namely cisplatin, carboplatin and oxaliplatin, clinically employed as antitumor drugs, trans- and cis-[Pt(Cl)(2)(pyridine)(2)] and cis-[Pt(Cl)(2)(pyridine)(5-SO3H-isoquinoline)] complexes, previously investigated also as potential telomerase inhibitors. In particular, long incubation times have been chosen in order to understand the fate of the complexes in the cells. For this purpose, sub-acute drug concentrations must be employed and, therefore, a very sensitive method of analysis like as inductively coupled plasma mass spectrometry (ICP-MS) superior to the widely employed atomic absorption spectroscopy (AAS) has been adopted. Any relationships among uptake/accumulation. and several parameters such as drug structure, lipophilicity, drug concentration and incubation time have been sought and analyzed: the bulk of data point for a passive diffusion mechanism through the cell membrane. (C) 2003 Elsevier Inc. All rights reserved.

引用

页码：73 / 78

页数：6

共 42 条

[1] Alberts B., 2002, Molecular Biology of The Cell, V4th
[2] Andrews PA, 2000, CANC DRUG DISC DEV, V7, P89
[3] ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35
[4] ANDREWS PA, 1988, CANCER RES, V48, P68
[5] Electrochemotherapy of tumours resistant to cisplatin: a study in a murine tumour model
Cemazar, M
Miklavcic, D
Mir, LM
Belchradek, J
Bonnay, M
Fourcault, D
Sersa, G
[J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (09) : 1166 - 1172
[6] An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells
Chen, ZS
Mutoh, M
Sumizawa, T
Furukawa, T
Haraguchi, M
Tani, A
Saijo, N
Kondo, T
Akiyama, SI
[J]. EXPERIMENTAL CELL RESEARCH, 1998, 240 (02) : 312 - 320
[7] Might telomerase enzyme be a possible target for trans-Pt(II) complexes?
Colangelo, D
Ghiglia, A
Viano, I
Mahboobi, H
Ghezzi, A
Cassino, C
Osella, D
[J]. JOURNAL OF INORGANIC BIOCHEMISTRY, 2004, 98 (01) : 61 - 67
[8] Cis-[Pt(Cl)2(pyridine)(5-SO3H-isoquinoline)] complex, a selective inhibitor of telomerase enzyme
Colangelo, D
Ghiglia, AL
Viano, I
Cavigiolio, G
Osella, D
[J]. BIOMETALS, 2003, 16 (04) : 553 - 560
[9] In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands
Coluccia, M
Nassi, A
Boccarelli, A
Giordano, D
Cardellicchio, N
Locker, D
Leng, M
Sivo, M
Intini, FP
Natile, G
[J]. JOURNAL OF INORGANIC BIOCHEMISTRY, 1999, 77 (1-2) : 31 - 35
[10] Particular aspects of platinum compounds used at present in cancer treatment
Desoize, B
Madoulet, C
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 42 (03) : 317 - 325

← 1 2 3 4 5 →